Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (711-720 of 713) with videos related to

Pageof 72
Sort By:
You have reached the last page of results.This site can display upto 713 results.
The Journal of Clinical Investigation|September 4, 2013
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cellsPaolo Neviani, Jason G Harb, Joshua J Oaks, et al.
Leukemia & Lymphoma|July 15, 2020
Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patientsBei Hu, Xiao Lin, Hans C Lee, et al.
Journal for Immunotherapy of Cancer|December 27, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemiaMichael Boyiadzis, Michael R Bishop, Rafat Abonour, et al.
Pageof 72

Showing results (711-720 of 713) with videos related to

Sort By:
Pageof 72
You have reached the last page of results.This site can display upto 713 results.
The Journal of Clinical Investigation|September 4, 2013
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cellsPaolo Neviani, Jason G Harb, Joshua J Oaks, et al.
Leukemia & Lymphoma|July 15, 2020
Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patientsBei Hu, Xiao Lin, Hans C Lee, et al.
Journal for Immunotherapy of Cancer|December 27, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemiaMichael Boyiadzis, Michael R Bishop, Rafat Abonour, et al.
Pageof 72